Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trialBrad H. Rovin, Catarina Almeida, Donald E. Kohan et al.|The Lancet|2023Cited by 264
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trialHiddo J.L. Heerspink, Toby Coates, Jai Radhakrishnan et al.|The Lancet|2023Cited by 214
Artificial intelligence and machine learning in nephropathologyJan U. Becker, Badrinath Roysam, David Mayerich et al.|Kidney International|2020Cited by 107
Targeting the Alternative Complement Pathway With Iptacopan to Treat IgA Nephropathy: Design and Rationale of the APPLAUSE-IgAN StudyDana V. Rizk, Jonathan Barratt|Kidney International Reports|2023Cited by 59
Effect of Immunosuppressive Drugs on the Changes of Serum Galactose-Deficient IgA1 in Patients with IgA NephropathyMin Jeong Kim, Jonathan Barratt|PLoS ONE|2016Cited by 33